Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 13/20 | 1.00 |
| ▸ | VCP | P55072 | 7/20 | 1.00 |
| ▸ | AMY1A | P0DUB6 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | DEGS1 | O15121 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 1.00 |
| ▸ | PIM3 | Q86V86 | 1/20 | 1.00 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 1.00 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 1.00 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.85 |
| ▸ | GAA | P10253 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26125550 | 1.00 | ALOX5 (1.00) | ALOX5VCPAMY1AMAPTALOX15 | |
| SCHEMBL14825241 | 0.92 | MAPT (1.00) | ALOX5VCPAMY1AMAPTALOX15 | |
| SCHEMBL12297672 | 0.85 | ALOX5 (0.89) | ALOX5VCPAMY1AMAPTALOX15 | |
| SCHEMBL12297190 | 0.85 | ALOX5 (0.74) | ALOX5VCPAMY1AMAPTALOX15 | |
| SCHEMBL2755470 | 0.85 | VCP (1.00) | ALOX5VCPAMY1AMAPTALOX15 | |
| SCHEMBL12298240 | 0.85 | ALOX5 (0.94) | ALOX5VCPAMY1AMAPTALOX15 | |
| SCHEMBL1887335 | 0.85 | ESR1 (1.00) | ALOX5VCPAMY1AMAPTALOX15 | |
| SCHEMBL1822974 | 0.85 | ALOX5 (0.88) | ALOX5VCPAMY1AMAPTALOX15 | |
| SCHEMBL1882991 | 0.85 | VCP (1.00) | ALOX5VCPAMY1AMAPTALOX15 | |
| SCHEMBL29152948 | 0.85 | ALOX5 (1.00) | ALOX5VCPAMY1AMAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119300037-A | Cross-domain authentication method and system under vehicle-mounted ad hoc network | 西安邮电大学 | 2025-01-10 | — | — | CN | claimed |
| EP-4181906-A1 | SPHINGOID COMPOUNDS FOR USE IN PROPHYLAXIS AND/OR THERAPY OF CORONAVIRIDAE INFECTION | Harbins Ruhr Bioscience, Inc. (US) | 2023-05-24 | — | — | EP | claimed |
| US-20230107927-A1 | METHODS OF TREATING IATROGENIC AUTOIMMUNE COLITIS | FIRST WAVE BIO, INC. | 2023-04-06 | — | — | US | claimed |
| WO-2022015348-A1 | SPHINGOID COMPOUNDS FOR USE IN PROPHYLAXIS AND/OR THERAPY OF CORONAVIRIDAE INFECTION | Harbins Ruhr Bioscience, Inc. (US) | 2022-01-20 | — | — | WO | claimed |
| EP-3863616-A2 | SPHINGOID COMPOUNDS FOR USE IN THE PROPHYLAXIS AND/OR THERAPY OF A VIRAL INFECTION | Harbins Ruhr Bioscience, Inc. (US) | 2021-08-18 | — | — | EP | claimed |
| US-20180110757-A1 | METHODS OF TREATING PRURITIS AND PAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-04-26 | — | — | US | claimed |
| US-20170252311-A1 | SPHINGOSINE KINASE INHIBITORS AND CERAMIDE FOR MAINTENANCE THERAPY OF GLIOBLASTOMA | SIGNPATH PHARMA INC. | 2017-09-07 | — | — | US | claimed |
| US-9687477-B2 | Modulation of sphingosine 1-phosphate metabolizing enzymes for the treatment of negative-strand RNA virus infections | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2017-06-27 | — | — | US | claimed |
| US-20150126564-A1 | MODULATION OF SPHINGOSINE 1-PHOSPHATE METABOLIZING ENZYMES FOR THE TREATMENT OF NEGATIVE-STRAND RNA VIRUS INFECTIONS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2015-05-07 | — | — | US | claimed |
| US-20140056917-A1 | FTY720 Increases CD74 Expression and Sensitizes Cancer Cells to Anti-CD74 Antibody-Mediated Cell Death | IMMUNOMEDICS, INC. (US) | 2014-02-27 | — | — | US | claimed |
| WO-2012166859-A2 | MODULATION OF SPHINGOSINE 1-PHOSPHATE METABOLIZING ENZYMES FOR THE TREATMENT OF NEGATIVE-STRAND RNA VIRUS INFECTIONS | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2012-12-06 | — | — | WO | claimed |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | claimed |
| WO-2010129954-A1 | TREATMENT OF ISCHEMIA-REPERFUSION INJURY | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-11-11 | — | — | WO | claimed |
| US-7220764-B2 | Such as 5-(2,4-dihydroxy-benzylidene)-3-(4-methoxy-phenyl)-2-thioxo-thiazolidin-4 -one; for treating/preventing hyperproliferative disease, autoimmune disease, inflammatory disease, or allergy | THE PENNSYLVANIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-05-22 | — | — | US | claimed |
| US-20040034075-A1 | Sphingosine kinase inhibitors | THE PENNSYLVANIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2004-02-19 | — | — | US | claimed |
| WO-2003105840-A2 | SPHINGOSINE KINASE INHIBITORS | THE PENNSYLVANIA STATE RESEARCH FOUNDATION (US) | 2003-12-24 | — | — | WO | claimed |
| WO-2026104911-A1 | FAST ANTENNA CALIBRATION BY ORTHOGONAL CARRIER SOUNDING (FACOCS) | TEJAS NETWORKS LIMITED (IN) | 2026-05-21 | — | — | WO | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-7220764-B2 | Such as 5-(2,4-dihydroxy-benzylidene)-3-(4-methoxy-phenyl)-2-thioxo-thiazolidin-4 -one; for treating/preventing hyperproliferative disease, autoimmune disease, inflammatory disease, or allergy | THE PENNSYLVANIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-05-22 | — | — | US | disclosed |
| WO-2006019586-A2 | METHOD OF TREATING TRAUMA OR SEPSIS | HAUSER CARL J (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | ALOX5 254/4885VCP 3891/4885AMY1A 2663/4885 |
| US-20040034075-A1 | Sphingosine kinase inhibitors | SPHK1, SPHK2, S1PR1 | ALOX5 439/4885VCP 4626/4885AMY1A 3249/4885 |
| US-20180110757-A1 | METHODS OF TREATING PRURITIS AND PAIN | CYSLTR2, LTB4R2, CYSLTR1 | ALOX5 84/4885VCP 3631/4885AMY1A 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.